Influenza A virus (IAV) infections are still a major global threat for humans, especially for the risk groups of young children and the elderly. Annual epidemics and sporadically occurring pandemics highlight the necessity of effective antivirals that can limit viral replication. The currently licensed antiviral drugs target viral factors and are prone to provoke viral resistance. In infected host cells IAV induces various cellular signaling cascades. The Raf/MEK/ERK signaling cascade is indispensable for IAV replication because it triggers the nuclear export of newly assembled viral ribonucleoproteins (vRNPs). Inhibition of this cascade limits viral replication. Thus, next to their potential in anti-tumor therapy, inhibitors targeting the Raf/MEK/ERK signaling cascade came into focus as potential antiviral drugs. The first licensed MEK inhibitor Trametinib (GSK-1120212) is used for treatment of malignant melanoma, being highly selective and having a promising side effect profile. Since Trametinib may be qualified for a repurposing approach that would significantly shorten development time for an anti-flu use, we evaluated its antiviral potency and mode of action. In this study, we describe that Trametinib efficiently blocks replication of different IAV subtypes in vitro and in vivo. The broad antiviral activity against various IAV strains was due to its ability to interfere with export of progeny vRNPs from the nucleus. The compound also limited hyper-expression of several cytokines. Thus, we show for the first time that a clinically approved MEK inhibitor acts as a potent anti-influenza agent.
Introduction
Influenza A viruses (IAV) cause annual epidemics as well as worldwide pandemics, and thus are a persistent threat for humans. Protection by vaccination is limited by the commitment of the population to undergo annual "flu-shots" and by the potency of the vaccine. Moreover, there is no protection against infections with newly or unexpectedly emerging IAV strains. Thus, next to vaccination, efficient antivirals are needed. Currently licensed drugs exclusively target functions of viral proteins such as inhibitors of the neuraminidase or M2 ion channel blockers. As a fast replicating virus with a quite error prone polymerase IAV can rapidly adapt and develop resistances against these inhibitors. However, IAV not only depends on the function of its viral gene products, but also exploits cellular signaling cascades for its own replication. Consequently, numerous studies have already shown that inhibition of IAV-induced signaling pathways can limit viral replication, suggesting that inhibitors targeting virus-supportive cellular factors or cascades may be promising antivirals (Gasparini et al., 2014; Loregian et al., 2014; Ludwig, 2009; Ludwig et al., 2003; Planz, 2013) . Importantly, inhibition of cellular targets is generally thought to confer a high barrier to emergence of resistance (Lee and Yen, 2012; Ludwig, 2009; Planz, 2013; Watanabe and Kawaoka, 2015) . Different genome-wide functional screens revealed various cellular genes involved in regulation of viral replication (Watanabe and Kawaoka, 2015) , helping to identify new cellular drug targets for antiviral intervention. This includes autophagy regulated genes (Zhou et al., 2009 ), the proteasome (Haasbach et al., 2011) , redox-mediated pathways (Nencioni et al., 2007; Sgarbanti et al., 2011) and different cellular kinases (Börgeling et al., 2014; Perwitasari et al., 2015; Pleschka et al., 2001; Root et al., 2000; Shin et al., 2007) .
Inhibition of cellular caspases impairs the passive nuclear export of viral ribonucleoprotein complexes (vRNPs), thereby negatively https://doi.org/10.1016/j.antiviral.2018.07.006 Received 5 June 2018; Received in revised form 5 July 2018; Accepted 6 July 2018 T affecting viral replication (Mühlbauer et al., 2015; Wurzer et al., 2003) . Likewise, NF-κB inhibition also affects release of vRNPs from the nucleus due to inhibition of caspase activity (Ehrhardt et al., 2013; Mazur et al., 2007) . For active export of progeny vRNPs, IAV strongly depends on the cellular nuclear export machinery. Consequently, viral replication can effectively be limited by targeting of nuclear export pathways using specific inhibitors such as leptomycin B (Watanabe et al., 2001) or verdinexor (Perwitasari et al., 2014) . In addition, serum-and glucocorticoid-regulated kinase 1 (SGK1) was shown to be required for vRNP export and consequently contributes to efficient viral replication (Alamares-Sapuay et al., 2013) .
Many virus-supportive cellular pathways are induced by IAV itself. Among these, the Raf/MEK/ERK kinase pathway fulfills important virus-supportive functions Pleschka et al., 2001) . Late in viral replication, HA proteins accumulate in lipid rafts at the cell membrane, leading to activation of this kinase cascade via protein kinase Cα which triggers the export of newly assembled vRNPs from the nucleus into the cytoplasm (Marjuki et al., 2006; Pleschka et al., 2001 ). An enhanced activation also correlated with increased viral replication and was mediated by higher viral polymerase activity leading to amplified HA accumulation (Marjuki et al., 2007) . The Raf/MEK/ERK signaling cascade belongs to the mitogen-activated protein kinase (MAPK) cascades (Roskoski, 2012) . It is most closely associated with the regulation of cell proliferation and mutations that lead to aberrant activation of this cascade are implicated in various human cancers. The kinase MEK stands at the bottleneck of this kinase pathway and accordingly MEK inhibitors can be used as therapeutic agents in oncology (Akinleye et al., 2013; Zhao and Adjei, 2014) . Because aberrant activation of Raf/MEK/ERK signaling also occurs in IAV infection, MEK inhibitors like U0126 have been shown to limit replication of various IAV strains (Droebner et al., 2011; Pleschka et al., 2001) . Treatment also reduced viral replication in vivo, indicating that these inhibitors may be potential agents to treat severe influenza disease (Droebner et al., 2011) .
Trametinib (GSK-1120212) is a selective allosteric ATP non-competitive inhibitor of the two isoforms MEK1 and MEK2 (Gilmartin et al., 2011; Yamaguchi et al., 2011) . It inhibits the MEK-dependent phosphorylation of ERK1 and ERK2 at amino-acid residues T202/Y204 or T185/Y187, respectively, thereby affecting growth of tumor cell lines with mutated BRAF or Ras (Gilmartin et al., 2011; Roskoski, 2012) . Trametinib acts very specific and is FDA-approved for the treatment of melanoma harboring BRAF V600 mutations (Akinleye et al., 2013; Infante et al., 2012; Wright and McCormack, 2013; Zhao and Adjei, 2014) .
In the present study, we aimed to investigate the antiviral properties of Trametinib against IAV. We identified Trametinib to effectively reduce both, viral titers and cytokine expression in vitro in various infected cell lines as well as viral replication in vivo thus being a promising candidate for a novel anti-influenza approach.
Material and methods

Cells, viruses, viral infections and standard plaque assay
Human alveolar type II epithelial cells (A549 cells) were cultivated in Dulbecco's modified Eagle's medium (Sigma-Aldrich) while MadinDarby canine kidney (MDCKII) cells were cultivated in minimum essential medium (Sigma-Aldrich). Media were supplemented with 10% fetal calf serum (Merck-Millipore) and cultivation performed at 37°C and 5% CO 2 under constantly humidified conditions. Primary human bronchial epithelial cells (HBEpC) were obtained from Promocell and handled as described earlier (Dudek et al., 2010) . The recombinant human influenza virus strain A/WSN/33 (WSN/H1N1) was generated by reverse genetics using the eight plasmid system (Hoffmann et al., 2000) . The influenza viruses A/FPV/Bratislava/79 (FPV/H7N7), A/ Puerto Rico/8/34 (Muenster variant) (Liedmann et al., 2014 ) (PR8M/ H1N1) and A/Victoria/3/75 (Victoria/H3N2) were taken from the virus strain collection of the Institute of Virology, Muenster. The origin of the A/Regensburg/D6/2009 (RB/H1N1pdm09) virus was described earlier (Droebner et al., 2011) . The avian IAV strain A/Mallard/Bavaria/1/ 2006 (Mallard/H5N1) was originally taken from the strain collection of the Planz laboratory at the Bundesanstalt für Viruserkrankungen der Tiere (BFAV), Tübingen, Germany, while A/Thailand/KAN-1/2004 (KAN-1/H5N1) was used with kind permission from P. Puthavathana (Bangkok, Thailand). The recombinant mouse-adapted laboratory strain SC35M (SC35M/H7N7) was obtained from the Institute of Virology, Freiburg, Germany. Depending on the virus strains used, experiments were performed in biological safety level 2 (BSL-2) or biological safety level 3 (BSL-3) laboratories. Infections were performed at a specific multiplicity of infection (MOI) as described earlier (Dudek et al., 2010) . Standard plaque assays were used to determine the number of infectious particles (Dudek et al., 2010) . After infection with human IAV, media for multi-cycle replication experiments were supplemented with trypsin (Invitrogen).
Inhibitors and treatment of infected or transfected cells
The inhibitor Trametinib (GSK-1120212) 4,6,7-tetrahydro-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d] pyrimidin-1(2H)-yl]phenyl]acetamide), a highly selective inhibitor of the two existing isoforms MEK1 and MEK2, was obtained from Active Biochem (purity of > 99% by HPLC) and dissolved in DMSO (Sigma-Aldrich). Oseltamivir carboxylate (designated as Oseltamivir) was purchased from Santa Cruz Biotechnology, dissolved in DMSO and used at a final concentration of 2 μM. Cells were pre-treated with inhibitors or DMSO for 1 h in media containing 10% FCS prior to infection or transfection. Afterwards cells were cultivated in the appropriate medium supplemented with inhibitor or DMSO for the indicated times. Staurosporine (STS, Sigma-Aldrich) dissolved in DMSO served as positive control for the induction of apoptosis.
Western blot analysis
Protein expression was analyzed by Western blot (WB) as described earlier (Kathum et al., 2016) . Polyclonal anti-PB1 (clone vK-20, Santa Cruz Biotechnology), polyclonal anti-ERK2 (clone C-14, Santa Cruz Biotechnology), monoclonal anti-PARP (clone 42, BD Transduction Laboratories) and monoclonal anti-NP (clone AA5H, Bio-Rad) primary antibodies were diluted 1:500-1:1000 in TBST buffer (Kathum et al., 2016) . Horseradish peroxidase-conjugated secondary antibodies antigoat IgG, anti-mouse IgG (Jackson ImmunoResearch Laboratories) or anti-rabbit IgG (Bio-Rad) were diluted 1:2500-1:5000 in TBST buffer.
Transient transfections and mini-genome assay
Cells were transfected using Lipofectamine ® 2000 transfection reagent (Invitrogen) according to the manufacturer's protocol. For stimulation with RNA, cells were transfected with 250 ng total RNA per 12-well isolated from A549 cells infected with IAV (MOI = 5) for 5 h (vRNA) or from uninfected A549 cells (cRNA) as control.
Viral polymerase activity in A549 cells was measured by minigenome assay using pHW72-luc (250 ng per 12-well) carrying a luciferase gene in negative orientation flanked by the viral promoter sequences (mini-genome) and plasmids encoding the three PR8/H1N1 polymerase subunits PB1, PB2, PA as well as NP (in pHW2000 backbone; each 250 ng per 12-well). 4-6 h post transfection medium was changed to fresh medium supplemented with inhibitor or DMSO. Luciferase activity was determined 24 h post transfection according to a standard protocol (Dudek et al., 2011) .
The siRNA transfections of A549 cells were conducted using Lipofectamine ® 2000 transfection reagent (Invitrogen) according to the manufacturer's protocol using a final siRNA concentration of 20 nM.
T. Schräder et al. Antiviral Research 157 (2018) 80-92 ERK1 siRNA, ERK1/2 siRNA and scrambled control siRNA (siCtrl) were purchased from Cell Signaling Technology. Six hours post transfection, medium was aspirated and the cell monolayer washed with PBS. Incubation in fresh medium was performed for additional 18 h. Then cells were infected with WSN/H1N1 (MOI = 5) and incubated for the indicated times before being subjected to immunofluorescence staining.
2.5. Analysis of cellular proliferation by MTT cell proliferation assay and apoptosis induction
To determine cellular proliferation, MTT assays were performed as described earlier (Dudek et al., 2010) . Induction of apoptosis in A549 and MDCKII cells was analyzed by detection of cleaved PARP (Oliver et al., 1998 ).
Immunofluorescence staining and microscopy
For immunofluorescence staining, infected A549 cells on cover glasses were washed with PBS (Sigma-Aldrich) and fixed with cold methanol (-20°C, Sigma-Aldrich) for 10 min at 4°C. Subsequently, cells were washed and blocked with 3% BSA (Carl Roth) in PBS (PBS-BSA) for 1 h at room temperature (RT). The primary anti-NP antibody (see chapter 2.3) diluted 1:600 in PBS-BSA was added for 1 h at RT. After washing, cells were incubated with a Cy™3-or Cy™5-labeled secondary anti-mouse IgG antibody (Jackson ImmunoResearch Laboratories) diluted 1:400 and DAPI (5 mg/ml) (4′,6-diamino-2-phenylindole, Thermo Fisher Scientific) diluted 1:10000 in PBS-BSA for 30-45 min at RT. After washing, mounting onto object slides was performed using Fluorescence Mounting Medium (Dako). Analysis was performed by epifluorescence microscopy (Axiovert 200M microscope, Carl Zeiss) or confocal laser scanning microscopy (LSM 780 microscope, Carl Zeiss). Epifluorescence pictures taken from eight different focal planes were used to generate maximum intensity projections (MIP) using the AxioVision V4.8.2.0 software (Carl Zeiss). CLSM pictures were either single focal planes or ortho projections. Ortho projections from several focal planes covering the whole cell were generated using the Zen 2.3 (blue edition) software (Carl Zeiss). Merged images of the two channels were generated using the software described before.
To evaluate cell morphology after infections, cells were fixed 24 h p.i. with 70% ethanol for 30 min at RT and analyzed using an inverted microscope (Axiovert 40 C, Carl Zeiss).
RNA isolation, cDNA synthesis and quantitative real-time PCR
RNA isolation, cDNA synthesis and quantitative real-time PCR was described earlier (Kathum et al., 2016) . Primers listed in Table 1 were used for quantitative real-time PCR.
Infection and treatment of mice
Inbred female 6-8 weeks old C57BL/6 mice, obtained from the animal breeding facilities at the Interfaculty Institute of Cell Biology, University Tuebingen (Germany), were infected as previously described (Droebner et al., 2011) using the virus doses indicated in the figure legends. The Institutional Animal Care and Use Committee of Tuebingen approved all animal studies.
To determine the effect on lung virus titers, Trametinib was applied twice daily (BID) per os (p.o.) in a concentration of 3 mg/kg, 1 mg/kg or 0.3 mg/kg bodyweight (BW) starting one hour prior to infection. DMSO served as solvent control. The application volume was 5 ml/kg BW. Stock solution was prepared by dissolving 6 mg Trametinib in 1 ml DMSO. 100 μl of stock solution were then further diluted with 300 μl Cremophor EL (Sigma, Germany) and 1600 μl PBS daily. Mice were sacrificed 24 h p.i. and lung virus titers were determined as described (Droebner et al., 2011) .
To determine body weight and analyze clinical symptoms, mice were randomly divided into two different study groups (solvent and Trametinib). Once daily mice were treated with 3 mg/kg BW p.o. as recommended by Gilmartin and colleagues (Gilmartin et al., 2011) , starting one hour prior to infection. Trametinib or solvent were administered by oral gavage at a dose volume of 5 ml/kg BW. Stock solution was prepared as described above. Treatment of mice was performed for five consecutive days. Bodyweight of infected mice was determined daily. When mice died or needed to be scarified due to regulations of the German animal protection law the bodyweight of the last day the mouse was alive was carried out to the end of the observation period (day 14 p.i.). Bodyweight is given as percentage for each individual mouse of the body weight at day 0.
Health status of mice was examined and protocoled twice daily. When health status changed within one day, the more severe conditions were taken into account. Health status was divided into four major categories: Breathing, group-behavior, posture (grade of kyphosis) and grooming. Each category was scored with either 1 (slight), 2 (medium) or 3 (severe). If no changes or symptoms were observed compared to uninfected mice in a particular category, the score was defined as 0. The termination criteria were the following: Total score of 9 or score of 3 in two categories. When mice died or needed to be scarified due to termination criteria the score was set to 4 for each category, leading to a total score of 16. This score was carried out to the end of the observation period (day 14 p.i.).
Statistical analysis and calculation of EC 50 values
Statistical significance was evaluated using GraphPad Prism software version 6.05. Test details of each experiment are described in the figure legends. The EC 50 value of Trametinib was calculated with GraphPad Prism software version 5.0.
Results
The MEK inhibitor Trametinib limits replication of human IAV strains and highly pathogenic avian IAV subtypes
Earlier studies described that MEK inhibitors can decrease viral replication (Droebner et al., 2011; Haasbach et al., 2013; Ludwig et al., 2004; Pleschka et al., 2001) . Based on these results we aimed to elucidate whether the MEK inhibitor Trametinib, which is already licensed for clinical use, also impairs IAV replication. We analyzed progeny viral Name Sequence
titers of human (WSN/H1N1) as well as avian IAV subtypes (FPV/ H7N7) in Trametinib-treated A549 cells to determine effective antiviral concentrations. Trametinib treatment resulted in a substantial reduction of progeny virus titers of both strains at micromolar concentrations ( Fig. 1A and B) . The effective inhibiting concentration slightly varied depending on the strain. For the 2009 pandemic RB1/H1N1pdm09 strain without pre-treatment the EC 50 was as low as 0.016 μM Trametinib (Fig. 1C) . We next assessed the effect of Trametinib on induction of cytopathogenic effect (CPE) in A549 cells infected with FPV/H7N7. Treatment with the chosen effective concentration of 20 μM Trametinib efficiently blocked virus-induced CPE (Fig. 1D ), confirming the inhibitory effect on viral replication on a macroscopic level. The same effect was also evident in cells infected with another H7N7 virus (SC35M/H7N7) as well as in case of infection with a H1N1 virus (PR8M/H1N1) (Fig. 1D) . Hence, we concluded that Trametinib can limit the replication of IAV. Next, multi-cycle viral growth kinetics of various IAV subtypes from 8 h to 48 h p.i. in presence of Trametinib were analyzed. Treatment consistently inhibited replication of the human IAV strain PR8M/H1N1 as well as the avian FPV/H7N7 strain with significantly reduced progeny viral titers at several different time points post infection (Fig. 1E , G). The efficacy varied between the different strains and time points analyzed. Lowest and most inconsistent titer reductions were detectable with the human IAV strain Victoria/H3N2 (Fig. 1F) . By use of another cell line, Madin-Darby canine kidney (MDCKII) cells, as well as primary human bronchial epithelial cells (HBEpC) we were able to exclude a cell-type specific limitation of Trametinib. Replication of human (WSN/H1N1, Victoria/H3N2) as well as avian IAV strains (FPV/H7N7) was significantly reduced in treated MDCKII cells ( Fig. 2A) as well as in HBEpC (Fig. 2B) , confirming that the antiviral effect is not limited to certain permanent cell lines but can also be observed in primary cells. As progeny virus titers of human IAV strains in HBEpC were relatively low we studied sensitivity of some additional IAV strains (KAN-1/H5N1, Mallard/H5N1, SC35M/H7N7) that by standard plaque assay. Shown are means ± SD of at least three independent experiments. Each experiment was performed in duplicate. Statistical significance was analyzed by two-way ANOVA followed by Sidak's multiple comparisons test.
replicated to higher progeny virus titers like FPV/H7N7. Indeed, replication of these viruses was also strongly affected by Trametinib (Fig. 2C) . Thus, Trametinib displays antiviral properties against different IAV subtypes including highly pathogenic avian IAV.
To compare the effect of Trametinib versus a classical antiviral compound, progeny viral titers from A549 as well as MDCKII cells (caption on next page) T. Schräder et al. Antiviral Research 157 (2018) 80-92 treated with Trametinib or the NA inhibitor Oseltamivir, or a combination of both, were analyzed. As expected, treatment with Trametinib reduced progeny virus titers in A549 and MDCKII cells ( Fig. 2D and E) . Strikingly, the presence of Trametinib reduced viral replication in MDCKII cells comparable to Oseltamivir (Fig. 2E) , whereas in A549 cells, Trametinib was even more effective (Fig. 2D) . Interestingly, in both cell lines, the combination of Trametinib and Oseltamivir reduced progeny virus titers stronger than the single treatment ( Fig. 2D and E).
Trametinib does not impair viability of treated cells
The risk of cytotoxic effect is always an issue when using cell directed inhibitors. Thus, the effect of Trametinib on cell proliferation and metabolic activity was analyzed by MTT assay. Trametinib did not influence proliferation and metabolic activity of A549, MDCKII and HBEpC after 8 h of treatment and metabolic activity was only slightly reduced without any concentration dependency after 24 h of treatment (Fig. 3A-C) . To analyze potential cell damaging pro-apoptotic effects, cleavage of PARP by caspases was determined by WB analysis in cells incubated with different concentrations of Trametinib for 24 h. Neither in A549 nor in MDCKII cells a strong induction of PARP cleavage was detectable (Fig. 3D) . Again, there were no concentration-dependent differences. These results confirmed that the antiviral activity of Trametinib is not due to unspecific cell toxic side-effects.
Trametinib limits IAV and vRNA induced cytokine expression
In addition to its virus-supportive function, activation of Raf/MEK/ ERK signaling is also an important mediator for the induction of cytokines (Kuderer et al., 2003; Wu et al., 2010) . Alterations of cytokine expression after Trametinib treatment of A549 cells was investigated 8 h p.i. with PR8/H1N1. Treatment with Trametinib significantly reduced virus-induced IFNβ and MxA mRNA expression, indicating an impairment of the cellular IFN response (Fig. 4A) .
In addition, the IAV-induced expression of IL-6 was significantly reduced by Trametinib (Fig. 4B) while expression of CCL5 (RANTES) and CXCL10 (IP10) was less severely reduced (Fig. 4B) . Interestingly, infection of cells with PR8M/H1N1 did not induce IL-8 mRNA expression, nevertheless Trametinib decreased its expression levels (Fig. 4B ). To exclude that the effect on cytokine expression was indirectly caused due to the impaired viral replication, Trametinib-treated A549 cells were transfected for 8 h with RNA from IAV-infected (vRNA) or mockinfected cells (cRNA). 5′-triphosphate-vRNA is regarded to be the major pathogen associated molecular pattern (PAMP) of IAV and represents here a non-dynamic viral stimulus, excluding that the observed reduction in virus-induced cytokine expression is solely due to reduced viral replication. The cellular vRNA-induced IFN response was not significantly altered by treatment with Trametinib, as shown by analysis of IFNβ and MxA mRNA expression (Fig. 4C) . In contrast to that, vRNAinduced expression of IL-6, IL-8, CCL5 and CXCL10 mRNA was Fig. 2 . Trametinib affects progeny virus titers of different IAV subtypes in MDCKII and human primary cells and acts synergistically with classical antivirals. After pre-treatment with the indicated substances (DMSO, Trametinib or Oseltamivir) or a combination of Trametinib and Oseltamivir (comb.), MDCKII (A, E), human primary HBEpC (B, C) or A549 cells (D) were infected with human (MOI 0.01 for WSN/H1N1 and Victoria/H3N2) or avian IAV subtypes (MOI 0.001 for FPV/H7N7, 0.01 for KAN-I/H5N1 and Mallard/H5N1) or with SC35M/H7N7 (MOI 0.01). After infection, cells were incubated with the indicated substances and progeny virus titers were determined 24 h p.i. by standard plaque assay. Titers of DMSO-treated cells were arbitrarily set to 100%. In addition, absolute virus titers are displayed in PFU/mL. Shown are means ± SD of at least three independent experiments. Each experiment was performed in duplicate (A-C) or triplicate (D, E). Statistical significance was evaluated by unpaired two-tailed t-test (A-C) or by one-way ANOVA followed by Dunnett's multiple comparisons test (D, E). Results are means ± SD of at least three independent experiments and are depicted as n-fold metabolic activity of untreated cells which was arbitrarily set to 1. Each experiment was performed in triplicate. As positive control cells were treated with 1 μM STS for the indicated times. (D) After 24 h treatment cells were lysed and cell lysates subjected to WB analysis to detect full-length as well as cleaved PARP. ERK2 was detected as loading control. As positive control A549 or MDCKII cells were treated with 1 μM or 0.5 μM STS respectively. Representative WB from at least three independent experiments are shown. significantly decreased in Trametinib-treated cells (Fig. 4D) indicating an involvement of the Raf/MEK/ERK cascade in the PAMP-induced cytokine induction. This demonstrated that Trametinib treatment directly leads to decreased cytokine expression independently of its effect on viral replication.
Trametinib mediates its antiviral activity by impaired nuclear export of progeny vRNPs
Next, we aimed to unravel the molecular mode of action of Trametinib's antiviral activity and focused first on viral RNA production. In PR8M/H1N1-infected A549 cells viral mRNA levels were rather elevated than reduced by Trametinib (Fig. 5A) . To analyze whether this is due to altered viral polymerase activity, mini-genome assays were performed, in which luciferase expression was indicative of viral polymerase activity in the absence of infection. In contrast to the viral mRNA expression data (Fig. 5A) , Trametinib substantially decreased luciferase activity indicating a reduced rather than enhanced viral polymerase activity (Fig. 5B) .
However, although these contradictory effects were clearly measurable, it seems as they would not be translated to later stages of the viral replication cycle, since viral protein synthesis was not affected at all (Fig. 5C) . Thus, the antiviral activity of Trametinib is not primarily due to interference with replication events prior to protein synthesis. Influenza viruses are nuclear replicating pathogens and thus have to transport newly produced genomes in form of vRNP complexes out of the nucleus. As it was shown previously that this is a Raf/MEK/ERKdependent event (Pleschka et al., Results are depicted as means ± SD of three independent experiments. Each experiment was performed in duplicate. Statistical significance was determined by two-way ANOVA followed by Sidak's multiple comparisons test. nuclear in early stages of the replication cycle (4 h p.i.), they were readily exported from the nucleus at later stages (8-10 h p.i.) (Fig. 6A ). An intermediate phenotype was detectable at 6 h p.i. where fluorescence was detectable in the nucleus as well as in the cytoplasm. Indeed, this export event was efficiently impaired in the presence of Trametinib. The compound led to a retention of vRNPs in the nucleus at later stages of infection (8-10 h p.i.) (Fig. 6A) . The same effect was also detectable in A549 cells infected with another H1N1 strain (PR8M/H1N1), where Trametinib also strongly blocked export of vRNPs from the nucleus into the cytoplasm (Fig. 6B ), leading to strong nuclear signals even at late time points post infection (Fig. 6C) .
To confirm that Trametinib-mediated inhibition of the Raf/MEK/ ERK signaling cascade indeed is responsible for the observed retention of vRNPs in the nucleus of infected cells, we performed siRNA-knockdown experiments targeting the MEK effectors ERK1 or both, ERK1 and 2. Transient knockdown of either ERK1 or ERK1/2 resulted in strong nuclear signals of NP at late time points post infection (Suppl. Fig. 1A and B), confirming that the inhibition of Raf/MEK/ERK signaling impairs export of vRNPs into the cytoplasm.
Thus, it can be concluded that Trametinib specifically inhibits viral replication by blocking nuclear export of progeny vRNPs.
Replication of IAV can also be limited by Trametinib in vivo resulting in improved clinical score and survival of treated animals
As Trametinib conferred promising antiviral properties against various IAV subtypes in vitro, its capability to limit viral replication was next tested in vivo in mice. Mice were orally treated BID with different concentrations of Trametinib or the solvent control. 24 h p.i. virus reduction in the lung of infected and treated animals compared to untreated controls was investigated. Trametinib treatment reduced virus propagation in the lung in a dose dependent manner ( Fig. 7A and B) . A dose of 3 mg/kg BID reduced progeny virus titers by more than one order of a magnitude. Thus, the antiviral action of Trametinib is also evident in vivo.
In addition, treatment of mice once daily for five consecutive days with 3 mg/kg Trametinib resulted in a reduced bodyweight drop compared to solvent treatment, which was detectable starting 4 days after infection (Fig. 7C) . Infected animals lost > 25% of bodyweight within 6 days after infection and consequently were euthanized. A drop of bodyweight was also found in Trametinib-treated mice; however, the lowest level was first reached at day 9 p.i. where animals had lost around 20% bodyweight. Thereafter, bodyweight increased again due to recovery of mice that survived the infection. Similar results were observed, when clinical symptoms were monitored (Fig. 7D) . Solventtreated mice developed disease symptoms very rapidly. Nine days after infection, all solvent-treated mice were dead, demonstrated by a clinical symptoms score of 16. Trametinib-treated mice also developed clinical symptoms. Influence of drug treatment was first visible at day 7 p.i. Peak of clinical symptoms was at day 11 p.i. Thereafter the clinical symptoms score declined (Fig. 7D) .
Survival of Trametinib-treated mice was demonstrated with a Kaplan-Meier estimate (Fig. 7E) . This analysis demonstrated a significant difference of Trametinib-treated mice compared to solvent controls (p = 0.0113). The median survival was 9.5 days compared to 5 days in favor to Trametinib treatment (data not shown). Results are depicted as n-fold viral mRNA expression of DMSO-treated cells, which was arbitrarily set to 1, and represent means ± SD of three independent experiments. Each experiment was performed in duplicate. Statistical significance was evaluated by unpaired two-tailed t-test. (B) Cells were transfected with plasmids expressing PB1, PB2, PA and NP (PPPN) along with a plasmid encoding luciferase under control of viral promoter sequences. As negative control transfection mix was lacking the PB1-encoding plasmid (PPN). After 24 h cultivation with Trametinib or DMSO luciferase activity was analyzed in the cell lysates. Results were calculated as n-fold of luciferase activity in PPN-transfected DMSO-treated cells which was arbitrarily set to 1 and are means ± SD of three independent experiments. Each experiment was performed in triplicate. Statistical significance was analyzed by two-way ANOVA followed by Sidak's multiple comparisons test. (C) Cells were lysed 6 h or 8 h p.i. and cell lysates used for WB analysis to evaluate PB1 and NP expression. ERK2 was detected as loading control. Viral protein expression at 8 h p.i. was evaluated by densitometry using Image J software. Viral protein expression is depicted as n-fold of the levels in infected cells that were treated with DMSO (arbitrarily set to 1). Shown are mean relative densities ± SD of at least three independent experiments. Statistical significance was analyzed by one-way ANOVA followed by Dunnett's multiple comparisons test.
Discussion
Influenza is still a severe threat for mankind. Our arsenal of antivirals against the flu is limited and we urgently need novel drugs against this disease. Since RNA viruses need the cellular machinery to replicate, we and others postulated that inhibition of virus-supportive cellular targets might be a novel approach, which also would help to overcome the problem of drug resistance (Lee and Yen, 2012; Ludwig, 2009; Planz, 2013; Watanabe and Kawaoka, 2015) . A big drawback of bringing a novel drug to the clinics is the very long time of development from basic research to the pharmacy, which easily can exceed 10 years or more. One way to reduce this development time would be repurposing of existing drugs licensed for other diseases.
The Raf/MEK/ERK kinase cascade is hyper-activated in many tumors, thus inhibition of this cascade on its bottleneck kinase MEK is a valuable tool in cancer therapy. Accordingly, many MEK inhibitors are now under preclinical and clinical development for use in oncology (Frémin and Meloche, 2010; Wang et al., 2007) . Aberrant signal transduction along this pathway does not only occur in tumor cells but also upon infection of cells with viruses (Pleschka, 2008) . We have shown quite early on, that the Raf/MEK/ERK signaling cascade is induced upon influenza A and B virus infection Pleschka et al., 2001) . Inhibiting activation of this cascade by the MEK inhibitor U0126 was shown to reduce viral replication suggesting that After infection cells were incubated with Trametinib (20 μM) or DMSO and fixed at the indicated times. Localization of vRNPs was analyzed by immunofluorescence staining of NP using Cy3-(A) or Cy5-labeled (B, C) secondary antibodies (red). Nuclear DNA was stained with DAPI (blue). Analysis was performed by epifluorescence microscopy (A) or confocal laser scanning microscopy (B, C). Representative images shown are either maximum intensity projections (MIP) of different focal planes (A), single focal planes (B) or ortho projections (C). Merged imaged were generated from both channels. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.) MEK inhibition presents a conceivable approach for novel antiviral therapies against IAV (Droebner et al., 2011; Planz, 2013; Pleschka et al., 2001) .
Here, we examined the first FDA-approved highly selective MEK inhibitor Trametinib (Gilmartin et al., 2011; Yamaguchi et al., 2011) that is in clinical use to treat metastatic melanoma (Wright and McCormack, 2013) . Clinical data are rapidly accumulating, demonstrating that the compound is well tolerated in humans, especially in early phases of treatment and does only show more severe side-effects upon long-term cancer treatment Infante et al., 2012; Kim et al., 2013) . Best of our knowledge we are the first to show that a fully licensed MEK inhibitor displays promising antiviral potential against IAV. Given the promising clinical side effect profile of this compound it would be well feasible to consider a short-term application of a MEK inhibitor to treat an acute disease such as influenza.
Mechanistically we were able to verify that Trametinib negatively affected progeny viral titers by promoting the retention of progeny vRNPs in the nucleus (Fig. 6) , which was previously also shown for other MEK inhibitors (Pleschka et al., 2001) . It should be stated, that detection of vRNP localization in infected cells was only performed indirectly by detection of NP that, however, is the core component of vRNPs and thus best suited to indicate its localization. In addition, Trametinib substantially inhibited the viral polymerase activity (Fig. 5B) . However, this did not correlate with decreased viral mRNA expression as there was even a slight increase in viral mRNA expression after treatment with Trametinib (Fig. 5A) , possibly due to a retention of template vRNA in the nucleus (Fig. 6 ) and viral protein expression was also unaffected (Fig. 5C) . Remarkably, our data also indicate that there are no major differences in the induction of apoptosis or the modulation of cell viability and cellular metabolism that might cause the observed antiviral effect of Trametinib (Fig. 3A-D) , underlining a specific mode of action.
The antiviral effect is independent of the cell line used, as it was observed in permanent cell lines like A549 and MDCKII as well as in primary HBEpC (Figs. 1 and 2) , verifying previous studies of another Raf/MEK/ERK inhibitor, that displayed antiviral activity in various cells (Pinto et al., 2011; Pleschka et al., 2001 (Fig. 2B) . This excluded that different replication behaviors are the sole factors determining the sensitivity for treatment with Trametinib. As the exact mechanism affecting the nuclear export of progeny vRNPs downstream of ERK remains unknown, it is also possible that differences in viral downstream targets of phosphorylated and thereby activated ERK are defining the susceptibility to inhibition of Raf/MEK/ERK signaling or that some virus strains might stronger depend on other pathways effecting nuclear export of progeny vRNPs e.g. induction of apoptosis (Wurzer et al., , 2003 . The severity of influenza is not only linked to viral replication but also to induction of cytokines. IAV are known to induce expression of cytokines in infected cells (Julkunen et al., 2000; Van Reeth, 2000) . As hyperactivation of cytokines, which is known as "cytokine burst", is a severe complication caused by infections with highly pathogenic avian influenza viruses (Cheung et al., 2002; de Jong et al., 2006) , it is valuable to limit the cytokine burden in addition to viral replication itself. Interestingly, several IAV-induced cytokines were reduced on mRNA level in presence of Trametinib ( Fig. 4A and B) . The expression of IFNβ and the interferon stimulated gene (ISG) MxA was only found to be reduced by Trametinib in infected cells (Fig. 4A ), but not strongly affected in vRNA-transfected cells (Fig. 4C) . Interestingly others also experienced a limited IFNβ expression in mouse primary alveolar epithelial cells (AECs) treated with the MEK inhibitor U0126 (Pinto et al., 2011) . Our results indicate that the cellular IFN response is not directly limited by Trametinib. Rather it seems to be primarily indirectly affected by reduced viral replication than being directly caused by deregulation of the Raf/MEK/ERK signaling cascade. Indeed, expression of IFNβ and MxA are not yet described to be directly regulated by the Raf/MEK/ERK signaling cascade. Considering Trametinib as antiviral drug it is beneficial that Trametinib does not directly alter the IFN response which is an important arm of cellular antiviral defense. A clearly decreased induction by Trametinib was also detectable for IL6, CCL5 and CXCL10 mRNA expression, which were induced by infection with PR8M/H1N1 (Fig. 4B) . IL-8 expression is described to be induced by the activation of the Raf/MEK/ERK cascade (Kuderer et al., 2003) . Although in A549 cells infected with PR8M/H1N1 we could not detect IL-8 induction as shown by Pinto and colleagues (Pinto et al., 2011) , there was strong down-regulation of constitutive mRNA expression levels (Fig. 4B) .
In addition to its properties to modulate cytokine expression, several facts underline the suitability of Trametinib as antiviral against IAV. Firstly, in vitro Trametinib exhibited an antiviral potency that was similar or even stronger than Oseltamivir ( Fig. 2D and E) . Secondly, Trametinib seems to act synergistically with Oseltamivir, comparable to what was shown for other MEK inhibitors . Thirdly, Trametinib also effectively limited replication of a 2009 pandemic H1N1 isolate (RB1/H1N1pdm09) in lungs of infected mice ( Fig. 7A and B) , confirming the effectiveness of MEK inhibitors in infected organisms (Droebner et al., 2011; Pinto et al., 2011) . Experiments showed a significant effect on survival when mice were treated with Trametinib compared to solvent controls. Nevertheless, overall survival was lower when compared to treatment with other MEK-inhibitors, such as CI-1040 (Haasbach et al., 2017) . One reason could be a different pharmacokinetic and bioavailability of Trametinib. Dosage and treatment schedule used here was based on pharmacokinetic studies published earlier (Gilmartin et al., 2011) . In this study, it was stated that half-life of the drug was 33 h. This was the reason, why Trametinib was given only once daily. Moreover, a concentration of 3 mg/kg was described to be sufficient to efficiently inhibit MEK. Based on the present data, it might be speculated that Trametinib needs to be given twice daily thereby increasing its antiviral effect. While these might be considerations for future development, the significant results regarding survival of mice (Fig. 7E ) generally indicates that treatment of IAV-infected mice with Trametinib can improve disease outcome.
According to data of us and others (Pinto et al., 2011) , there might be a two-way mode of action of MEK inhibitors like Trametinib: i) direct antiviral activity by blocking a step in the viral replication cycle and ii) inhibition of excess cytokine responses to limit the detrimental cytokine burst during infection.
Besides the anti influenza virus activity, recent results indicate that MEK inhibitors might not only be active against other viruses (Pleschka, 2008) but also against bacterial infections, that represent a major complication in severe influenza (Bruchhagen et al., 2018) . While these studies are still in an early stage, they highlight the potential potency of MEK inhibitors against various infectious agents.
While several MEK inhibitors have been described to confer antiinfluenza activity Planz, 2013) , here we show for the first time that a clinically approved MEK inhibitor displays antiviral characteristics in vitro as well as in vivo. This may open significant opportunities in terms of a repurposing approach. This also includes a potential combination therapy together with classical antivirals such as Oseltamivir as already suggested previously . The clinical safety data that are published Infante et al., 2012; Kim et al., 2013) or that are accumulating along the current use of Trametinib in oncology may well be used to shorten development time of the drug for an anti-influenza use.
